Benefits of Danazol Treatment in Patients With Hemophilia A (Classic Hemophilia)

Harvey R. Gralnick
In: JAMA: The Journal of the American Medical Association · 1985 · vol. 253(8) , pp. 1151 · doi:10.1001/jama.1985.03350320075020 · PMID:3918188 · W1978614772
article OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-15 ⓘ

Danazol treatment increased factor VIII activity and reduced hemorrhagic episodes in patients with hemophilia A, though this research does not relate to endometriosis or adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Danazol, an attenuated androgen, was given intermittently in three patients with hemophilia A. The rise in factor VIII activity with danazol treatment was associated with a fivefold decrease in hemorrhagic episodes and plasma concentrate product utilization when compared with similar periods without the drug. Four other patients with moderate hemophilia A who received danazol for 14 days had an increase of 400% to 850% in their factor VIII levels. Of four patients without detectable levels of factor VIII who were treated with danazol, two had elevations of the factor VIII level, to 3% and 4%, respectively. Danazol appears to be an effective treatment for patients with hemophilia A.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (4)

References (9)

Cited by (4)

Source provenance

openalex
last seen: 2026-05-10T10:36:00.256005+00:00
License: CC0 · commercial use OK